Skip Navigation
Explore our COVID-19 Resources and Updates
CHS blue logo square
 
 
Home > Our Work > All Publications > 2001

Publications

Our publications keep professionals working across the public, private, and academic sectors informed on the most important developments and issues in health security and biosecurity.

Find an article or report by keywords:

 
 
Find an article or report or see all by area, author, or year:

Title:

Hemorrhagic Fever Viruses as Biological Weapons: Medical and Public Health Management

Authors:
Luciana Borio, Thomas Inglesby, C. J. Peters, et al. for the Working Group on Civilian Biodefense
Date posted:
May 08, 2001
Publication type:
Article
Publication:

JAMA 2002;287(18):2391-2405

Publisher:
American Medical Association
Availability:
Available on publisher's website
See also:

Full article as HTMLPDF

Introduction:

Objective: To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population.

Participants: The Working Group on Civilian Biodefense included 26 representatives from academic medical centers, public health, military services, governmental agencies, and other emergency management institutions.

Evidence: MEDLINE was searched from January 1966 to January 2002. Retrieved references, relevant material published prior to 1966, and additional sources identified by participants were reviewed.

Consensus Process: Three formal drafts of the statement that synthesized information obtained in the evidence-gathering process were reviewed by the working group. Each draft incorporated comments and judgments of the members. All members approved the final draft.

Conclusions: Weapons disseminating a number of HFVs could cause an outbreak of an undifferentiated febrile illness 2 to 21 days later, associated with clinical manifestations that could include rash, hemorrhagic diathesis, and shock. The mode of transmission and clinical course would vary depending on the specific pathogen. Diagnosis may be delayed given clinicians' unfamiliarity with these diseases, heterogeneous clinical presentation within an infected cohort, and lack of widely available diagnostic tests. Initiation of ribavirin therapy in the early phases of illness may be useful in treatment of some of these viruses, although extensive experience is lacking. There are no licensed vaccines to treat the diseases caused by HFVs.

Full article as HTMLPDF

 

 

Our Mission

To protect people’s health from epidemics and disasters and ensure that communities are resilient to major challenges.